Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal Cancer

The most common type of the renal cancers detected in humans is clear cell renal cell carcinomas (ccRCCs). These tumors are usually initiated by biallelic gene inactivation of the Von Hippel–Lindau (VHL) factor in the renal epithelium, which deregulates the hypoxia-inducible factors (HIFs) HIF1α and HIF2α, and provokes their constitutive activation irrespective of the cellular oxygen availability. While HIF1α can act as a ccRCC tumor suppressor, HIF2α has emerged as the key HIF isoform that is essential for ccRCC tumor progression. Indeed, preclinical and clinical data have shown that pharmacological inhibitors of HIF2α can efficiently combat ccRCC growth. In this review, we discuss the molecular basis underlying the oncogenic potential of HIF2α in ccRCC by focusing on those pathways primarily controlled by HIF2α that are thought to influence the progression of these tumors

Influencia del tamaño de los cortes, la congelación, almacenamiento congelado y descongelación en la producción de exudado en patas de cerdo deshuesadas

En la industria de los chacinados se suele utilizar –para cubrir faltantes de materia prima nacional– carne de cerdo importada. La misma se adquiere congelada y se la descongela en el momento de su utilización. Dicho proceso se lleva a cabo –muchas veces– en condiciones de temperatura y de circulación del medio de calentamiento (aire o agua) muy poco controladas, generando un alto volumen de exudado y la posibilidad de contaminación (Mascheroni, 2001). La pérdida de peso resultante puede depender de distintos parámetros del proceso: Condiciones de congelación y de almacenamiento, peso de la muestra, tiempo de almacenamiento, condiciones de descongelación, etc. Las condiciones de congelación generalmente no pueden ser controladas por el comprador, pero las otras si. Por ello el objetivo de este trabajo fue estudiar la influencia de distintas características del producto y del proceso de almacenamiento congelado y descongelación en la producción de exudado en patas de cerdo deshuesadas.Facultad de Ingenierí

p38MAPK and Chemotherapy: We always need to hear both Sides of the Story

The p38MAPK signaling pathway was initially described as a stress response mechanism. In fact, during previous decades, it was considered a pathway with little interest in oncology especially in comparison with other MAPKs such as ERK1/2, known to be target of oncogenes like Ras. However, its involvement in apoptotic cell death phenomena makes this signaling pathway more attractive for many cancer research laboratories. This apoptotic role allows to establish a link between p38MAPK and regular chemotherapeutic agents such as Cisplatin or base analogs (Cytarabine, Gemcitabine or 5-Fluorouracil) which are currently used in hospitals across the world. In fact, and more recently, p38MAPK has also been connected with targeted therapies like tyrosine kinase inhibitors (vg. Imatinib, Sorafenib) and, to a lesser extent, with monoclonal antibodies. In addition, the oncogenic or tumor suppressor potential of this signaling pathway has aroused the interest of the scientific community in evaluating p38MAPK as a novel target for cancer therapy. In this review, we will summarize the role of p38MAPK in chemotherapy as well as the potential that p38MAPK inhibition can bring to cancer therapy. All the evidences suggest that p38MAPK could be a double-edged sword and that the search for the most appropriate candidate patients, depending on their pathology and treatment, will lead to a more rational use of this new therapeutic tool

Detection of C1 inhibitor (SERPING1/C1NH) mutations in exon 8 in patients with hereditary angioedema: evidence for 10 novel mutations

Hereditary angioedema (HAE) is caused by mutations in the C1 inhibitor gene (SERPING1, C1NH) and the result is C1 inhibitor deficiency, either in levels or function. We have searched exon 8 for mutations by direct sequencing and analyzed the rest of the exons by SSCP in 87 Spanish families affected by HAE. Out of 87 screened families, we have detected exon 8 mutations in 26. Among these, 17 different mutations were identified: 14 point mutations and 3 frameshift. Seven of the point mutations and the three frameshift were not previously reported. Mutations were: S438P; R444P; V451G; W460X; V468D; G471E; X479R; S417fsX427; I440fsX450; E429fsX450. The rest of the families presented previously reported mutations, 5 missense and two nonsense. In none of the 26 families was an additional change identified in the rest of the exons by SSCP, and, in 20 out of the 22 families with point mutation, we verified that the mutation did not affect a healthy relative. Seven of these families had no history of the disease, and in five of them we were able to verify that the progenitors did not have the mutation. Therefore, they were de novo mutations

Colorectal Tumour Microsatellite Instability Test Results: Perspectives from Patients

<p>Abstract</p> <p>Purpose</p> <p>To determine which individuals with colorectal cancer (CRC) were interested in knowing the results of their tumour microsatellite instability (MSI) and immunohistochemistry (IHC) testing. We were also interested in the patients' reasons for choosing to learn their results and in the impact of those results on overall self-assessed quality of life.</p> <p>Patients and Methods</p> <p>CRCs from 414 individuals were assayed for MSI and IHC for DNA mismatch repair gene products (<it>MLH1</it>, <it>MSH2</it>, <it>MSH6</it>). Individuals were invited to learn their MSI/IHC results. They randomly received either brief or extended educational materials about the testing and a pretest survey to learn reasons for their interest and to assess their pretest quality of life.</p> <p>Results</p> <p>Of the 414 individuals, 307 (74%) chose to learn their results. There was no significant difference in interest in knowing test results according to gender, age, educational level, or family history of colon cancer. The level of detail in the information piece received by the patients did not influence their desire to know their test results. Self-assessed quality of life was not altered by receiving results and was not correlated with the test outcome.</p> <p>Conclusions</p> <p>Individuals with colorectal cancer had a high level of interest in learning their individual MSI/IHC test results and did not seem deterred by the inherent complexity or ambiguity of this information. Regardless of test outcome, results did not significantly affect self-assessed quality of life. Further studies are needed to assess comprehension of results and behavioural changes resulting from the learning of MSI/IHC results.</p

ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology

© 2021 The Authors.Sorafenib is a multikinase inhibitor widely used in cancer therapy with an antitumour effect related to biological processes as proliferation, migration or invasion, among others. Initially designed as a Raf inhibitor, Sorafenib was later shown to also block key molecules in tumour progression such as VEGFR and PDGFR. In addition, sorafenib has been connected with key signalling pathways in cancer such as EGFR/EGF. However, no definitive clue about the molecular mechanism linking sorafenib and EGF signalling pathway has been established so far. Our data in HeLa, U2OS, A549 and HEK293T cells, based on in silico, chemical and genetic approaches demonstrate that the MEK5/ERK5 signalling pathway is a novel target of sorafenib. In addition, our data show how sorafenib is able to block MEK5-dependent phosphorylation of ERK5 in the Ser218/Tyr220, affecting the transcriptional activation associated with ERK5. Moreover, we demonstrate that some of the effects of this kinase inhibitor onto EGF biological responses, such as progression through cell cycle or migration, are mediated through the effect exerted onto ERK5 signalling pathway. Therefore, our observations describe a novel target of sorafenib, the ERK5 signalling pathway, and establish new mechanistic insights for the antitumour effect of this multikinase inhibitor.This work was supported by grants from Fundación Leticia Castillejo Castillo, Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-094093-B-I00) to RSP and MJRH. OR holds a contract for accessing the Spanish System of Science, Technology, and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM) and received partial support from the European Social Fund (FSE) through its Operative Program for Castilla-La Mancha (2007–2013). RSP and MJRH's Research Institute, and the work carried out in their laboratory, received partial support from the European Community through the FEDER. RPS and EAL hold a research predoctoral contract cofounded by the European Social Fund and UCLM. The Spanish Ministry of Economy and Competitiveness (MINECO, Project RTI2018-096724-B-C21) and the Generalitat Valenciana (PROMETEO/2016/006) support work in the Encinar´s laboratory. Authors are grateful to Dr.G- Ferrer Mayorga for her assistance in the transwell assays, and to the ‘Centro de Computación Científica’ (CCC-UAM) for letting us to take advantage of the computer cluster Cibeles (https://www.ccc.uam.es/) and for providing computing facilities

Rest-frame optical continua of L ~ L*, z>3 quasars: probing the faint end of the high z quasar luminosity function

Near-IR photometry for 20 radio-loud z>3 quasars, 16 of which are radio- selected, are presented. These data sample the rest-frame optical/UV continuum, which is commonly interpreted as emission from an accretion disk. In a previous study, we compared the rest-frame optical/UV continuum shapes of 15 optically bright (V3 quasars with those of 27 low redshift (z~0.1) ones that were matched to the high redshift sample in evolved luminosity (i.e. having luminosities ranging from 1-7 times the characteristic luminosity, L*, where L*~(1+z)^{~3}) to look for signs of evolution in the central engines. We found the continuum shapes at z~0.1 and z>3 similar, consistent with no significant change in the ratio mdot/M, where mdot is the accretion rate with respect to the Eddington rate and M is the black hole mass. This study expands our earlier high redshift sample to lower luminosity, away from extreme objects and towards a luminosity overlap with lower redshift samples. The distribution of rest-frame optical/UV continuum shapes for this fainter sample is broader, extending further to the red than that of the brighter z>3 one. Three quasars from this fainter sample, two radio-selected and one optically-selected, have optical continuum slopes alpha<-1 (F_{nu}~nu^{alpha}). The optically-selected one, LBQS0056+0125, appears to be reddened by dust along the line of sight or in the host galaxy, whereas the radio-selected ones, PKS2215+02 and TXS2358+189, could derive their red continua from the contribution of a relatively strong synchrotron component to the rest-frame optical. These objects may represent a bridge to a population of very red high redshift quasars to which ongoing or future near-IR, optical and deep X-ray surveys will be sensitive.Comment: 16 pages, 6 figures; accepted for publication in MNRA

Identification of non-coding genetic variants in samples from hypoxemic respiratory disease patients that affect the transcriptional response to hypoxia

A wide range of diseases course with an unbalance between the consumption of oxygen by tissues and its supply. This situation triggers a transcriptional response, mediated by the hypoxia inducible factors (HIFs), that aims to restore oxygen homeostasis. Little is known about the inter-individual variation in this response and its role in the progression of disease. Herein, we sought to identify common genetic variants mapping to hypoxia response elements (HREs) and characterize their effect on transcription. To this end, we constructed a list of genome-wide HIF-binding regions from publicly available experimental datasets and studied the genetic variability in these regions by targeted re-sequencing of genomic samples from 96 chronic obstructive pulmonary disease and 144 obstructive sleep apnea patients. This study identified 14 frequent variants disrupting potential HREs. The analysis of the genomic regions containing these variants by means of reporter assays revealed that variants rs1009329, rs6593210 and rs150921338 impaired the transcriptional response to hypoxia. Finally, using genome editing we confirmed the functional role of rs6593210 in the transcriptional regulation of EGFR. In summary, we found that inter-individual variability in non-coding regions affect the response to hypoxia and could potentially impact on the progression of pulmonary diseases.Ministerio de Ciencia e Innovación (Spanish Ministry of Science and Innovation, MICINN) [SAF2011 24225 to LdelP, SAF2014-53819-R to L.delP., B.J.]; Comunidad Autónoma de Madrid [S2010/BMD-2542 to L.delP., F.G.R., J.A.], Sociedad Española de Neumología y Cirugía Torácica (SEPAR) [34/2013 to LdelP, F.G.R.]; Fondo de Investigación Sanitaria/Instituto de Salud Carlos III [PI13-01512 to F.G.R.]; Fundación Caja Madrid (Beca de Movilidad para Profesores de las Universidades Públicas de Madrid 2011–2012 to L.delP); Canadian Institutes of Health Research (CIHR) [MOP-82875 to W.W.W.]; Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN355532-10 to W.W.W.]; National Institutes of Health [1R01GM084875 toW.W.W.]; CSIC (Spanish National Research Council) [JAE-Doc grant-2010 to O.R., in part by the European Social Fund]. Spanish science, technology and innovation contract [University of Castilla-LaMancha-2014 to O.R., in part by the European Social Fund]. Funding for open access charge: MICINN [SAF2011 24225 to L.delP., SAF2014-53819-R to L.delP., B.J.

Corrigendum to 'Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression?' [Journal of Neuroimmunology, 233 (2011) 221-227]

The authors regret that one of the author names for this article was presented incorrectly in the printed version. ‘Olga R. Bocharova’ should have been ‘Olga A. Bocharova’. The correct presentation of the author names can be seen above and in the online version of this paper. The authors would like to apologise for any inconvenience caused

ERK5 Is a major determinant of chemical sarcomagenesis: implications in human pathology

Sarcomas are a heterogeneous group of tumors in which the role of ERK5 is poorly studied. To clarify the role of this MAPK in sarcomatous pathology, we used a murine 3-methyl-cholanthrene (3MC)-induced sarcoma model. Our data show that 3MC induces pleomorphic sarcomas with muscle differentiation, showing an increased expression of ERK5. Indeed, this upregulation was also observed in human sarcomas of muscular origin, such as leiomyosarcoma or rhabdomyosarcoma. Moreover, in cell lines derived from these 3MC-induced tumors, abrogation of Mapk7 expression by using specific shRNAs decreased in vitro growth and colony-forming capacity and led to a marked loss of tumor growth in vivo. In fact, transcriptomic profiling in ERK5 abrogated cell lines by RNAseq showed a deregulated gene expression pattern for key biological processes such as angiogenesis, migration, motility, etc., correlating with a better prognostic in human pathology. Finally, among the various differentially expressed genes, Klf2 is a key mediator of the biological effects of ERK5 as indicated by its specific interference, demonstrating that the ERK5–KLF2 axis is an important determinant of sarcoma biology that should be further studied in human pathology.This work has been supported with Grant RTI2018-094093-B-I00 funded by MCIN/AEI/10.13039/501100011033, “ERDF A way of making Europe” to RSP. Also supported with funds from Fundación Leticia Castillejo Castillo, Roche España and ACEPAIN to RSP and MJRH. RSP and MJRH’s Research Institute and the work carried out in their laboratory, received partial support from the European Community through the FEDER. JJ and EAL hold a predoctoral research contract cofounded by the European Social Fund and UCLM. OR holds a contract for accessing the Spanish System of Science, Technology, and Innovation (SECTI) funded by the University of Castilla-La Mancha (UCLM) and received partial support from the European Social Fund (FSE) through its Operative Program for Castilla-La Mancha (2007–2013)